Year All20242023202220212020201920182017201620152014 Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris October 20, 2023 Read More Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range October 18, 2023 Read More Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing October 16, 2023 Read More Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023 October 02, 2023 Read More Abivax files registration statement for proposed initial public offering in the United States September 29, 2023 Read More Abivax announces the release of its 2023 half-year financial report September 29, 2023 Read More Abivax presents first-half 2023 financial results September 21, 2023 Read More Abivax provides business and operational update September 07, 2023 Read More Abivax appoints Patrick Malloy as Senior Vice President Investor Relations August 23, 2023 Read More Abivax secures up to EUR 150M from two structured debt financing transactions August 21, 2023 Read More
Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris October 20, 2023 Read More
Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range October 18, 2023 Read More
Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing October 16, 2023 Read More
Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023 October 02, 2023 Read More
Abivax files registration statement for proposed initial public offering in the United States September 29, 2023 Read More
Abivax secures up to EUR 150M from two structured debt financing transactions August 21, 2023 Read More
